Phospholamban anticorps (pThr17)

N° du produit ABIN7265288

Cet anticorps anti-Phospholamban est un anticorps Lapin Polyclonal détectant Phospholamban dans IHC. Adapté pour Humain, Rat et Souris.

Aperçu rapide pour Phospholamban anticorps (pThr17) (ABIN7265288)

Antigène: Phospholamban (PLN)

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Phospholamban est non-conjugé

Application: Immunohistochemistry (IHC)

Détail du produit anti-Phospholamban anticorps

Épitope: pThr17

Attributs du produit: Phosphorylated antibody

Purification: Affinity purification

Immunogène: A phospho specific peptide corresponding to residues surrounding T17 of human PLN

Isotype: IgG

Information d'application

Indications d'application: IHC 1:50-1:200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Avoid freeze / thaw cycles.

Détails sur Phospholamban

Antigène: Phospholamban (PLN)

Autre désignation: PLN

Sujet: The protein encoded by this gene is found as a pentamer and is a major substrate for the cAMP-dependent protein kinase in cardiac muscle. The encoded protein is an inhibitor of cardiac muscle sarcoplasmic reticulum Ca(2+)-ATPase in the unphosphorylated state, but inhibition is relieved upon phosphorylation of the protein. The subsequent activation of the Ca(2+) pump leads to enhanced muscle relaxation rates, thereby contributing to the inotropic response elicited in heart by beta-agonists. The encoded protein is a key regulator of cardiac diastolic function. Mutations in this gene are a cause of inherited human dilated cardiomyopathy with refractory congestive heart failure, and also familial hypertrophic cardiomyopathy.

ID gène: 5350

UniProt: P26678

Pathways: Negative Regulation of Transporter Activity